Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial

Hai-Zhen YANG; Ke WANG; Hong-Zhong JIN; Tian-Wen GAO; Sheng-Xiang XIAO; Jin-Hua XU; Bao-Xi WANG; Fu-Ren ZHANG; Chun-Yang LI; Xiao-Ming LIU; Cai-Xia TU; Su-Zhen JI; Yang SHEN; Xue-Jun ZHU.
Chinese Medical Journal ; (24): 1845-1851, 2012.
Artículo en Inglés | WPRIM | ID: wpr-283707

Documentos relacionados

  1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
  2. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
  3. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
  4. Indicaciones y Complicaciones del Implante de Marcapasos Endocárdico Percutáneo Definitivo en Paciente del Hospital Militar Central de El Salvador en el Periodo de Enero 2018 a Diciembre 2021
  5. Tumor necrosis factors-α inhibition-induced paradoxical psoriasis: A case series and literature review.
  6. Long lasting response to anti-tumor necrosis factor α agents in psoriasis: A real life experience.
  7. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
  8. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
  9. Five-year experience with infliximab: Follow up of the product familiarisation program.
  10. Pharmacological and residual effects in randomized placebo-controlled trials. A structural causal modelling approach.